Posts by Mourabit Halima

China, Japan, and other Asian countries have some of the highest rates of gastric cancer worldwide. In China, the majority of patients are still diagnosed at an advanced stage, having already lost the opportunity for curative surgery. Effective systemic therapy is therefore essential for improving survival. In recent years, innovative drugs represented by antibody–drug conjugates (ADCs)—such as the HER2-targeted ADC trastuzumab deruxtecan (T-DXd)—have achieved major breakthroughs in pivotal clinical studies including DESTINY-Gastric04. These advances are expected to gradually transform the treatment landscape starting from later lines of therapy. Asian clinical researchers have played an important role in these studies, contributing insights that are redefining clinical practice.

In the second-line treatment of hormone receptor–positive, HER2-negative (HR+/HER2–) advanced breast cancer, CDK4/6 inhibitors combined with fulvestrant have become the standard of care. However, variations in efficacy and safety profiles among different inhibitors remain an important clinical consideration.

At the 2025 ESMO Annual Congress, the overall survival (OS) data from the monarchE trial were released, showing that abemaciclib combined with endocrine therapy significantly improved survival in patients with HR+/HER2- high-risk early breast cancer, reducing the risk of death by 15.8%.

Editor’s Note: With its remarkable therapeutic efficacy, DS-8201 has dramatically reshaped the treatment landscape for patients with advanced breast cancer. In HER2-positive advanced breast cancer, DS-8201 has firmly established its…